Skip to main content
PLOS One logoLink to PLOS One
. 2021 Jun 1;16(6):e0248523. doi: 10.1371/journal.pone.0248523

Sleeping pattern and activities of daily living modulate protein expression in AMD

Kaushal Sharma 1,2, Ramandeep Singh 3, Suresh Kumar Sharma 4, Akshay Anand 1,*
Editor: Alfred S Lewin5
PMCID: PMC8168906  PMID: 34061866

Abstract

Degeneration of macular photoreceptors is a prominent characteristic of age-related macular degeneration (AMD) which leads to devastating and irreversible vision loss in the elderly population. In this exploratory study, the contribution of environmental factors on the progression of AMD pathology by probing the expression of candidate proteins was analyzed. Four hundred and sixty four participants were recruited in the study comprising of AMD (n = 277) and controls (n = 187). Genetics related data was analyzed to demonstrate the activities of daily living (ADL) by using regression analysis and statistical modeling, including contrast estimate, multinomial regression analysis in AMD progression. Regression analysis revealed contribution of smoking, alcohol, and sleeping hours on AMD by altered expression of IER-3, HTRA1, B3GALTL, LIPC and TIMP3 as compared to normal levels. Contrast estimate supports the gender polarization phenomenon in AMD by significant decreased expression of SLC16A8 and LIPC in control population which was found to be unaltered in AMD patients. The smoking, food habits and duration of night sleeping hours also contributed in AMD progression as evident from multinomial regression analysis. Predicted model (prediction estimate = 86.7%) also indicated the crucial role of night sleeping hours along with the decreased expression of TIMP-3, IER3 and SLC16A8. Results revealed an unambiguous role of environmental factors in AMD progression mediated by various regulatory proteins which might result in intermittent AMD phenotypes and possibly influence the outcome of anti-VEGF treatment.

1. Introduction

Most of the degenerative diseases (e.g. AMD and Alzheimer’s disease) have shown complex phenotypes based on both gene-environment interactions which have propensity to alter the cellular functions by gene expression changes [1, 2]. AMD is characterized by degenerative changes in macular photoreceptors and vision impairment in elderly. It is associated with various environmental factors and 52 independent genetic loci [3]. However, most of reported AMD alleles have not been probed for interaction with environmental factors rendering the genetic studies of AMD an incomplete and unimpactful analysis.

AMD literature is replete with evidence in support of the contribution of both genetic and environmental factors in the progression of AMD, but fails to define the architecture of this complex phenotype. However, smoking has been much investigated with context to AMD and found to exhibit its effect through generation of oxidative stress [4] and induce angiogenic cascade [5, 6] in order to promote angiogenesis of choroidal blood vessels. Moreover, smoking exposure has been shown to exert the pathological changes akin to AMD by blocking alternative complement pathways and by lipid dysregulation in RPE cells [7]. Studies have also shown that the combined effect of both alcohol consumption and smoking might further exacerbate the AMD pathology by influencing the activity of SOD (superoxide dismutase) and glutathione peroxidase activity [8]. Our previous reports have also defined the pathological role of oxidative stress [9], impaired angiogenesis [10, 11] and inflammatory cascade (mediated through CCL2 and CCR3) [1214]. Similar pathological hallmarks have also been exhibited by other degenerative diseases including AD, ALS etc. [1518]. Recently, we have also identified genetic variants of TIMP3, APOE and HTRA1 genes to contribute towards the complexity of Indian AMD [19]. The exact mechanism of action of the associated environmental factors to modulate the function wide genetic architecture in AMD is not adequately investigated although it is generally accepted to play a key role in AMD pathology. Exposure of environmental factors is possibly to bring the epigenetic modifications at the gene/genome (methylation of CpG Island) as well as on histone protein (acetylation, phosphorylation, methylation, citrullination, ubiquitylation, ribosylation, and sumoylation) levels which could modulate the expression of proteins and their mediated cellular mechanism [1]. Temporal nature of smoking and dietary induced AMD pathology by altering the protein expression indicates the epigenetic regulation of disease progression [20]. Revealing the understanding of rare and common genetic variants, copy number variations along with mitochondrial genetics, and their contributions in the AMD pathology under the influence of environmental factors, enable us to redefine the diagnosis and propose a new therapeutics regimen [2123].

We report that there is an alteration in expressions of HtrA Serine Peptidase 1 (HTRA1), Tissue inhibitor of metalloproteinase-3 (TIMP-3) and Immediate Early Response 3 (IER-3) in sleep deprived individuals or AMD patients with increase in sleep duration, prompting further research [24, 25]. This has implication for superior diagnosis and management of patients affected by AMD. We wanted to examine the nature and extent of the role of environmental factors in exerting its influence on genetic components and whether these are governed by epigenetic or epistatic interactions.

2. Materials and methods

2.1. Recruitment of participants

We have recruited around 464 participants in present study which comprised with both AMD (n = 277) and controls (n = 187). Participants were recruited as per the inclusion-exclusion criteria mentioned in the study along with their informed written consent. The study has started the recruitment of participants from 2010 and finished the same in 2017. The recruitment of participants and clinical examinations were performed from the Department of Ophthalmology, PGIMER, Chandigarh, India and experiments were conducted in Neuroscience Research Lab, PGIMER, Chandigarh, India. The study was conducted as per the approval of Institute Ethical Committee of both PGIMER (No: PGI/IEC/2005-06; dated: 23.07.2013) and Panjab University (IEC No. 131A-1, dated: 29.10.2014). All methods pertaining to study were performed in accordance with the relevant guidelines and regulations laid down by IECs. The study could be considered as a representative to replicate the same in large cohort.

2.2. Clinical investigations

Clinical evaluation of AMD phenotypes was carried out by retina specialists which included fluorescein fundus angiography (FFA) of dilated retina of the patients. Patients were clinically classified based on the drusen deposits and leaky vessels captured as fundus images. Moreover, the extent of macular photoreceptors degeneration and thickness of retinal layers were also examined by Optical Coherence Tomography (OCT) of patients. AMD patients were classified based on the clinical features observed and stratified by the AREDS criteria. Based on the presence of clinical parameters including drusen, neovascular lesions and atrophy of photoreceptors, AREDS stratified the AMD patients into 5 categories. Briefly, AMD patients with A few small drusen (<63 microns in diameter) fall in the AREDS 1. AREDS2 was characterized as multiple small drusen, a few intermediate drusen (63 to 124 microns in diameter), and/or RPE abnormalities. Many intermediate drusen with at least one large druse (≥125 microns in diameter) classified as AREDS3. Atrophy of foveal photoreceptors was characterized as greographic atrophy (AREDS4) and finally, patients with any leakage between retinal layers or neovascular features were classified as AREDS5.

2.3. Activities for daily living (ADL) details

A well-defined questionnaire was introduced to collect the socio-demographic details of the studied participants. ADL details prominently included the daily living activities (food habits, smoking, alcohol), education and profession, any medication, physical activities and/or yogic practices, sleeping pattern, etc which mostly associated with person’s life style. Food habit was categorized i.e. vegetarian, prior history of non-vegetarian and/or non-vegetarian, based on the consumption of food for at least six months or more since the date of recruitment. Non-vegetarian participant was defined based on consumption of chicken, fish and/or mutton or any one of them. Smokers were also categorized (non-smoker, prior/past-smoker, current smoker) based on the current and/or past-history of smoking, if any, of the participants who must be smoking for minimum six months (in case of prior or current smoker) at the time of recruitment. Similarly, participants were also classified (non-alcoholic, prior/past-alcoholic and current alcoholic) based on the alcohol consumption (past or current) with minimum 6 months of alcohol consumption history. To see the impact of sleep hours of the participants, we have classified participants in to three categories namely as sleep deprived (<6 hours sleep), 6–7 hours’ sleep and rise before 6AM (6–7 hours’ sleep) and >6–7 hours’ sleep and late sleep or late rise (after 6AM). Moreover, we also have asked participants whether they have been instructed to take medication for any ailment including cardiovascular, hypertension, diabetes, migraine and stroke history by a physician in addition to AMD.

2.4. Serum extraction

3ml of blood sample was withdrawn from participants and were subjected to centrifugation at 2500rpm for 30minutes. Upper supernatant layer was collected and stored at -80°C for further experimentation.

2.5. Total protein estimation

Total protein in the serum of participants was estimated by Bradford’s method. Samples were diluted (ranges from 200–600 times) with distilled water before performing the assay. Bradford’s reagent was added in 1:4 dilutions in the experiment. Absorbance of samples was taken at 595nm by ELISA reader (BioRad, USA).

2.6. ELISA

Serum levels of proteins involved in pro-angiogenesis (e.g. ADAMTS9, TIMP-3), cellular regulatory proteins (like IER-3, B3GALTL, HTRA1), monocarboxylic acid (pyruvic acid or lactate) transporter (SLC16A8) and lipid metabolizing proteins [hepatic lipase (LIPC) and apolipoprotein E (APOE)] were estimated using commercially available ELISA kit. Protocol was followed as per available recommendations with the kit and absorbance was recorded at 450nm. Values of ELISA were normalized with total protein of the respective sample. Levels of protein were compared with control populations.

2.7. Genotype analysis

Genotype analysis was also carried out for same set of genes involved in various cellular functions e.g. lipid metabolizing proteins [LIPC (rs920915) and APOE (rs769449)], pro-angiogenesis [e.g. ADAMTS9 (rs6795735), TIMP-3 (rs5749482)], cellular regulatory proteins [like IER-3 (rs3130783), B3GALTL (rs9542236), HTRA1 (rs11200638)] and monocarboxylic acid transporter [e.g. SLC16A8 (rs8135665)] to associate with ADL.

2.8. Statistics

Data was assessed for normal distribution in the population using normal quantile plot (O-Q plot) and Kolmogorov-Smirnos (K-S) tests. Differential protein expression in various groups stratified on the basis of socio-demographic details, was analyzed by ANOVA. Logistic regression analysis was utilized to analyse the effect of exposure of environmental factors (like smoking, food habit, alcohol consumption etc) by creating variables for prior and current status of activities of daily living (ADL). To examine the differential protein expression due to gender polarization effect in AMD patients, contrast analysis was carried out. Predictive modeling based on clinical severity and associated expression changes were analyzed by regression analysis. Multinomial regression analysis was done to analyze the contribution of ADL in AMD severity. Moreover, the prediction model based on ADL and expression level of proteins was put forwarded to diagnose AMD cases more precisely.

3. Results

3. 1. Association of socio-demographic factors

Chi-square analysis of the data revealed a significant association of various factors with AMD patients including profession, accident, consumption of anti-inflammatory drugs of participants. There is a significant difference between mean age of AMD and Control (p<0.001). Results reveal marginal association of physical activity and education of an individual with AMD pathology (Table 1).

Table 1. Comparative demographic characteristics of AMD and controls.

Features AMD(n) Controls(n) p-value
Gender
    1. Male 171 (61.73%) 99 (53.51%) 0.833
    2. Female 106 (38.27) 86 (46.87%)
Age (Mean ± SD) 68.30 ± 9.086 56.94 ± 11.266 <0.0001***
Anti-Inflammatory drugs¥ <0.0001***
    1. No Inflammatory 144 (53.33%) 139 (81.76%)
    2. Anti-Inflammatory drugs 126 (46.67%) 31 (18.24%)
Occupation¥ <0.0001***
    1. Professional 62 (22.63%) 8 (5.19%)
    2. Semi professional 48 (17.52%) 6 (3.90%)
    3. Clerical 41 (14.96%) 37 (24.03%)
    4. Skilled 07 (2.56%) 13 (8.44%)
    5. Semi-skilled 12 (4.38%) 28 (18.18%)
    6. Unskilled 103 (37.59%) 62 (40.26%)
    7. Unemployed 01 (0.36%) 0
Education¥ 0.063
    1. Professional or honor 61 (22.18%) 46 (28.57%)
    2. Graduate or Post Graduate 21 (7.64%) 20 (12.42%)
    3. Intermediate 23 (8.36%) 18 (11.18%)
    4. High school 74 (26.91%) 35 (21.74%)
    5. Middle school 19 (6.91%) 15 (9.32%)
    6. Primary school 57 (20.73%) 19 (11.80%)
    7. Illiterate 20 (7.27%) 08 (4.97%)
Physical activity¥ 0.052
    1. Physically active 111 (40.81%) 78 (49.37%)
    2. Inactivity 161 (59.19%) 80 (50.63%)
Accident history¥ 0.029*
    1. Accident history 55 (19.93%) 18 (11.69%)
    2. No accident history 221 (80.07%) 136 (88.31%)

¥ Some missing values.

Activities of daily living (ADL) of the participants were also analyzed to examine if association existed between AMD and these variables. Association of AMD patients with BMI, smoking habits (both prior and current habit) and abnormal sleeping pattern was noted. Moreover, it was higher in AMD patients as compared to control (Table 2).

Table 2. Comparative frequencies of activities of daily livings (like BMI, smoking, alcohol consumption, food habit and sleeping pattern) of AMD and control participants.

Features AMD (n) Controls (n) p-value
BMI¥ 0.003*
    1. Under weight 10 (3.75%) 07 (4.46%)
    2. Normal 175 (65.54%) 87 (55.41%)
    3. Over Weight 50 (18.73%) 53 (33.76%)
    4. Obese 32 (11.98%) 10 (6.37%)
Smoking habit¥ 0.010*
    1. Never smoker 185 (67.52%) 128 (81.01%)
    2. Prior smoker 54 (19.71%) 17 (10.76%)
    3. Current smoker 35 (12.77%) 13 (8.23%)
Alcohol consumption 0.650
    1. Never Alcohol 186 (67.15%) 112 (71.34%)
    2. Prior Alcohol 30 (10.83%) 14 (8.92%)
    3. Current Alcohol 61 (22.02%) 31 (19.74%)
Food habit ¥ 0.163
    1. Vegetarian 147 (53.26%) 78 (50%)
    2. Non-vegetarian 86 (31.16%) 61 (39.10%)
    3. Prior nonveg 43 (15.58%) 17 (10.90%)
Night sleeping hours¥ 269 0.006*
    1. 6–7 hrs sleep, rise before 6AM 157 (58.36%) 81 (54.36%)
    2. Sleep deprived (<6hrs sleep) 29 (10.78%) 05 (3.35%)
    3. >7–8 sleep, late sleep or late rise (after 6AM) 83 (30.86%) 63 (42.29%)

¥ Some missing values.

Frequencies of clinical features of AMD patients were also calculated as presented in Table 3. Recruited AMD patients showed advanced form of AMD clinical features (AREDS 5) involving bilateral phenotype. Further dissection of bilateral phenotypes of AMD patients revealed the numbers as 28, 34 and 82 with bilateral dry, bilateral wet and dry-wet bilateral phenotypes, respectively. Approximately, 42% of AMD patients were also diagnosed with and cataract and underwent the surgery to treat the same.

Table 3. Clinical characteristics of North-West Indian AMD recruited in the study.

AMD features Phenotypes Number Percent (%)
AMD phenotypes
Dry AMD 42 15.2
Wet AMD 91 32.9
Bilateral AMD 144 52.0
Cataract¥ No cataract 157 57.30
Unilateral Cataract 53 19.34
Bilateral cataract 64 23.36
Eye surgery¥ No eye surgery 160 64.78
Unilateral surgery 96 35.03
Bilateral surgery 18 06.57

¥ Some missing values.

3.2. Activities of daily living influence protein expression

We also attempted to study the gross impact of various ADL on protein expressions in AMD patients. Our results revealed a significantly enhanced LIPC levels in AMD patients who smoke and have non-vegetarian food habits (prior) suggesting an impaired lipid metabolism (IDL to LDL formation) due to malfunction of LIPC in AMD pathology (Fig 1A & 1E). Interestingly, the sleeping pattern of AMD patients [6-7hrs sleep, waking time before 6AM in morning (normal sleep) versus >7-8hrs sleep, late sleep or late wakefulness] was found to display a significant effect on HTRA1 levels. Documentation of consequently altered HTRA1 levels suggests the role of impaired circadian rhythm on AMD patients and the biological significance of HTRA1 being amenable to such regulation. However, more research is required (Fig 1G). We did not find significant alteration in protein levels under the influence of smoking, participant’s food habits and disturbed sleeping pattern (Fig 1B–1D, 1F and 1H).

Fig 1. Expression of protein under ADL.

Fig 1

Expression of lipid metabolizing (LIPC and APOE), proagniogenic (TIMP3 and ADAMTS9), regulatory (HTRA1, B3GALTL, and IER3) and momocarboxylic acid transporter (SLC16A8) proteins under the influence of ADL. LIPC (pg/ug) levels were significantly elevated in ‘current smoker’ AMD patients (A & E). Altered sleeping patter can be associated with HTRA1 levels in AMD pathology indicating the crucial role of circadian rhythm in degenerative diseases like AMD (G).

The beta coefficient (B) of logistic regression analysis revealed that significantly decreased expression of IER-3 (-0.288), B3GALTL (-0.214), LIPC (-0.172), TIMP-3 (-63.696) along with increased levels of HTRA1 (0.696) were observed in Indian AMD, without adjusting the ADL. Logistic regression analysis estimated the individual effect of either prior or current status of ADL on protein expressions in AMD pathology (Table 4). Similar results were noted by adjusting smoking and alcohol habits. Past history of alcohol consumption was also found to significantly decrease IER3, B3GALTL, LIPC, TIMP3 expressions and increase HTRA1 levels. Additionally, prior history of alcohol consumption has potential to modulate the AMD pathology by -0.641 unit as compared to those who consume vegetarian diet (95% CI = 0.278–0.998; P = 0.049). Prior non-vegetarian history revealed marginal association with AMD by modulating the expression of HTRA, B3GALTL, IER3, LIPC and TIMP3 with changing it -0.691 (B = beta coefficient) unit with reference to never smoker (95% CI = 0.233–1.076; P = 0.076). Interestingly, by adjusting the sleeping pattern of AMD patients, it decreased the expression of IER3 (B = -.351; 95% CI = .605-.819; P = <0.0001) and TIMP3 (B = -44.128; P = <0.0001) significantly. Moreover, altered sleeping pattern (person who slept late or woke up after sun rise) revealed the changes in the expression of IER3 and TIMP3 by 0.757 unit (B coefficient) as compared to normal sleep (95% CI = 1.2–3.785; P = 0.01). Significant changes in IER3 (B = -.314; 95% CI = .637-.838; P = <0.0001), TIMP3 (B = -41.969; P = <0.0001) and SLC16A8 (B = -0.184; 95% CI = 1.022–1.415; P = 0.027) expression were observed while adjusting the physical activity of AMD patients (Table 4). Our results support the previous findings which indicate the crucial contribution of environmental factors including smoking, food habits, physical activity and alcohol consumption in AMD pathology by regulating the proteins expression. The association of sleeping pattern with AMD shows the biological importance of HTRA1, IER3 and TIMP3 which may have roles in modulating age-related changes in retinal layers, representative of AMD pathology.

Table 4. Logistic regression analysis to estimate the changes in protein expression under the influence of ADL.

Variables in the Equation
  B S.E. Wald Df Sig. Unadjusted 95% C.I.
Lower Upper
Step 5e IER3 levels -.288 .066 19.371 1 <0.0001 .749 .659 .852
  B3GALTL levels -.214 .065 11.037 1 0.001 .807 .711 .916
  HTRA1 levels .696 .149 21.744 1 <0.0001 2.006 1.497 2.687
  LIPC levels -.172 .081 4.539 1 0.033 .842 .719 .986
  TIMP3 levels -63.696 8.666 54.027 1 <0.0001 .000 .000 .000
  Constant 1.484 .220 45.353 1 0.000 4.412    
B S.E. Wald df Sig. Adjusted for smoking 95% C.I.
Lower Upper
Step 1a IER3 levels -.287 .066 18.980 1 <0.0001 .751 .660 .854
  B3GALTL levels -.214 .064 11.335 1 0.001 .807 .713 .914
  HTRA1 levels .690 .147 21.984 1 <0.0001 1.994 1.494 2.660
  LIPC levels -.171 .082 4.345 1 0.037 .843 .717 .990
  TIMP3 levels -62.852 8.660 52.672 1 <0.0001 .000 .000 .000
  Smoking code     1.649 2 0.438      
  Smoking code(1) -.507 .395 1.648 1 0.199 .602 .278 1.306
  Smoking code(2) -.049 .494 .010 1 0.920 .952 .361 2.508
  Constant 1.538 .226 46.431 1 0.000 4.657    
B S.E. Wald df Sig. Adjusted for Alcohol 95% C.I.
Lower Upper
Step 1a IER3 levels -.291 .068 18.513 1 <0.0001 .748 .655 .854
  B3GALTL levels -.222 .065 11.756 1 0.001 .801 .705 .909
  HTRA1 levels .707 .151 21.784 1 <0.0001 2.028 1.507 2.728
  LIPC levels -.185 .083 4.983 1 0.026 .831 .706 .978
  TIMP3 levels -63.702 8.623 54.572 1 <0.0001 .000 .000 .000
  Alc code     5.397 2 0.067      
  Alc code(1) -.679 .441 2.374 1 0.123 .507 .214 1.203
  Alc code(2) -.641 .326 3.870 1 0.049 .527 .278 .998
  Constant 1.705 .246 47.879 1 0.000 5.502    
  B S.E. Wald df Sig. Adjusted for Food habit 95% C.I.
Lower Upper
Step 1a IER3 levels -.286 .067 18.201 1 <0.0001 .751 .659 .857
  B3GALTL levels -.209 .065 10.368 1 .001 .811 .714 .921
  HTRA1 levels .674 .149 20.503 1 .000 1.963 1.466 2.628
  LIPC levels -.163 .081 4.017 1 .045 .850 .724 .996
  TIMP3 levels -63.781 8.722 53.475 1 <0.0001 .000 .000 .000
  Food Habit code     3.219 2 .200      
  Food Habit code(1) -.058 .286 .040 1 .841 .944 .539 1.655
  FoodHabit_code(2) -.691 .390 3.140 1 .076 .501 .233 1.076
  Constant 1.613 .255 40.018 1 .000 5.018    
B S.E. Wald df Sig. Adjusted for sleeping 95% C.I.
Lower Upper
Step 1a IER3 levels -.351 .077 20.720 1 < .0001 .704 .605 .819
  TIMP3 levels -44.128 7.184 37.735 1 < .0001 0.000 .000 .000
  Night Slp code     8.606 2 .014      
  Night Slp code(1) -.568 .616 .851 1 .356 .567 .169 1.895
  Night Slp code(2) .757 .293 6.666 1 .010 2.131 1.200 3.785
  Constant 1.367 .239 32.617 1 .000 3.923    
  B S.E. Wald df Sig. Adjusted for Physi activity 95% C.I.
Lower Upper
Step 1a IER3 levels -.314 .070 20.140 1 < .0001 .730 .637 .838
  TIMP3 levels -41.969 6.908 36.913 1 < .0001 .000 .000 .000
  SLC16A8 levels .184 .083 4.913 1 .027 1.202 1.022 1.415
  Physi Activ code(1) -.039 .263 .022 1 .883 .962 .574 1.611
  Constant 1.350 .276 23.919 1 .000 3.859    

3.3. Gender polarization effects of SLC16A8 and LIPC expressions in AMD

Females are considered to be more susceptible for AMD pathology, though we did not find any significant difference in frequency of AMD male and female. We also attempted to examine the gender effect on protein expression in Indian AMD patients. Contrast estimate was done using univariate analysis of variance to analyze the difference in protein expressions among male and female of studied population (Table 5). Contrast estimate (CE) for SLC16A8 [CE = -0.768; F = 5.451; 95% CI = -1.418- (-)-0.119; P = 0.021] and LIPC [CE = -0.644; F = 7.357; 95% CI = -1.112- (-)-0.175; P = 0.007] was found to be significantly decreased between male and female control population. Such differential expression of both proteins was not observed among AMD male and female. It may be argued that differential expression of both SLC16A8 and LIPC is required to regulate various mechanisms under the influence of a set of hormones and may confer the protective mechanism for age-related changes.

Table 5. Contrast estimate using univariate analysis of variance to differentiate the expression pattern on basis of gender for control population.

Variables F-value Contrast estimate (CE) p-value 95% CI
Lower Higher
SLC16A8 5.451 -0.768 0.021 -1.418 -0.119
LIPC 7.357 -0.644 0.007 -1.112 -0.175

[Female (n) = 86; male (n) = 99].

3.4. ADL contribution in advancement of AMD severity

To assess the independent contribution of ADL (including smoking, food habits, physical activity, sleeping hours and alcohol consumption) on AMD severity (AREDS criteria), we subjected the data to multinomial logistic regression. The model demonstrated a highly significant association of both past (B = -1.286; P = <0.0001) and current non-vegetarian food habit (B = -0.667; P = 0.001) in the advancement of AMD pathology (Table 6). Results showed that current non-vegetarian and past history of non-vegetarian history can contribute to AMD by B values of -0.667 and -1.286 units as compared to reference category (vegetarian diet). However, the prediction of model was not satisfactory.

Table 6. Multinomial logistic regression to examine the contribution of ADL in AMD severity.

Parameter estimates
Parameters B S.E. Wald df p-value
Food habit Non-vegetarian -0.667 .198 11.388 1 0.001
Prior Non-vegetarian -1.286 .247 27.020 1 <0.0001
Smoking Past smoker -1.275 .288 19.572 1 <0.0001
Current smoker -2.435 .390 39.054 1 <0.0001
Night Sleep hours Sleep deprived (<6hrs sleep) -1.885 .311 36.716 1 <0.0001
>7-8hrs sleep, late sleep or late rise -.681 .195 12.206 1 <0.0001
 Alcohol Past Alcohol -1.803 .280 41.547 1 <0.0001
Current Alcohol -1.077 .209 26.619 1 <0.0001

Reference category: aVegetarian habit; anon-smoker habit; a6-7hours sleep or wake up before 6AM; aNever alcoholic.

Similarly, past and current status of smoking has also showed a significant association in progression of AMD pathology. Contribution of past (B = -1.275; P = <0.0001) and current smoking (B = -2.435; P = <0.0001) was observed in exacerbating the AMD pathology with prediction probability of around 68.4% (Table 6). Results for alcohol consumption in progression of AMD pathology has shown a comparable trend highlighting the contribution of past (B = -1.803; P = <0.0001) and current status of alcohol consumption (B = -1.077; P = <0.0001) as compared to reference category (Table 6). The prediction probability of the model was about 65%. Interestingly, sleep deprived (<6hours sleep) and >7-8hrs sleep, late sleep or late rise subjects have also shown the significant impact on progression of AMD severity. Results have shown that sleep deprived (B = -1.885; P = <0.0001) and >7-8hrs sleep, late sleep or late rise (B = -.681; P = <0.0001) patterns contribute to the progression of AMD severity with a prediction probability of about 60% (Table 6). Pearson and deviance values of Goodness-of-fit model were found to be non-significant for the analysis. Results are suggested an independent role of ADL (environmental factors), especially sleep, in the progression of AMD pathology-which has never been analyzed previously.

3.5. Altered sleeping pattern and expression of IER3, TIMP3 and SLC16A8 confer the AMD

Association of sleep pattern and AMD pathology has not been adequately investigated. We have attempted to further dissect the impact of sleeping pattern in AMD patients. Regression analysis shows that night sleeping hours (B = 0.449; Exp(B) = 1.567; 95% CI = 1.1–2.23; P = 0.013) along with the expression of IER3 (B = -.444; Exp(B) = 0.641; 95% CI = 0.512–0.804; P = <0.0001) and TIMP3 (B = -23.54; Exp(B) = <0.0001; 95% CI = 0.000–0.004; P = 0.010) are significantly associated with AMD pathology. However, the marginal association of SLC16A8 expression (B = -.332; Exp(B) = .717; 95% CI = 0.506–1.017; P = 0.062) was also observed (Table 7). Results suggest the imperative role of sleeping pattern of an individual which may activate the various age-related mechanisms by influencing pertaining protein expressions. Our results indicate the biological significance of IER3, TIMP-3 and SLC16A8 expression to be influenced by alter sleeping hours of an individual. Classification table also strengthens our hypothesis with 86.7% validity of this regression model to predict the AMD pathology.

Table 7. Regression analysis to predict the AMD pathology under the influence of ADL.

Variables in the Equation
  B S.E. Wald Df p-value Exp(B) 95% CI
Night sleep pattern .449 .180 6.205 1 0.013 1.567 1.1–2.23
TIMP3 levels -23.54 9.194 6.555 1 0.010 .000 0.000–0.004
IER3 levels -.444 .115 14.907 1 <0.0001 .641 0.512–0.804
SLC16A8 levels -.332 .178 3.487 1 0.062 .717 0.506–1.017
Constant .192 .445 .187 1 0.666 1.212
Classification table
Predicted
Group code Percentage corrected
AMD Controls
Group AMD 111 17 86.7
Control 22 50 69.4
Overall percentage 80.5

4. Discussion

Disease pathology of AMD is known to be influenced by both genetic and environmental factors evident by our quantitative outcome of protein expression under the influence of environmental factors [1]. In general, the ambiguity in the nature and extent of interaction between environmental and genetic factors has significantly hampered the pace of clinical translation in the field of AMD genetics [2]. Current AMD genetics warrants comprehensive analysis in the manner it can illustrate the contribution and interactions of contributory factors along with their degree of penetrance in disease progression. Majority of ageing diseases progress by cumulative genetic changes under temporal exposure of ADL consequently result in cellular and molecular alterations including protein homeostasis, metabolic dysfunction and aberrant signaling processes. The altered cellular and molecular crosstalk may confer complexity to the age related diseases thereby confounding an effective and precise diagnosis and treatment regime for complex disorders like AMD [26]. Therefore, a careful consideration of environmental and genetic components and their nature of interactions (and/or extent of interaction) may likely provide a precise AMD phenotype and personalized management strategies. The treatment strategy which can deal with the synergistic and/or cumulative action of contributory factors could provide a better outcome to therapies for AMD [26, 27]. Our ANOVA results demonstrate that smoking and non-vegetarian food habit can effectively alter the LIPC expression that may exacerbate the AMD pathology. Interestingly, altered expression of HTRA1 under the influence of altered sleep cycle, can accelerate the AMD pathology thereby providing opportunity to correct the dysregulated circadian rhythm.

Various studies have been carried out to illustrate the significance of environmental factors on genetic components. Our results show that smoking, gender, age, diet etc as contributing confounders and have been significantly associated with complement factors, CFH variant, other variants of other genetic loci including ARMS2, IL-8, TIMP3, SLC16A8, RAD51B, VEGFA etc [2831]. In our earlier report, smoking was found to be associated with TC genotype of CFH variant (Y402H) along with marginal association of AG genotype of TLR3 (rs3775291) with non-vegetarian food habit which also exhibited confounding effect on CFH expression and modulated TLR3 mediated functions in AMD [32, 33]. Interestingly, we also have found the pathological role of TIMP-3, SLC16A8, IER3 and LIPC in CFH independent manner in Indian AMD [34]. Moreover, eotaxin-2 was also significantly altered when smoker and non-smoker AMD cases were compared [35]. These results point out that the interaction between genetic and environmental factors which often lead to complex phenotype of disease [36].

Logistic regression analysis, by creating the dummy variables, enabled us to identify the effect of prior and current status of ADL like smoking and food habits etc. The results unambiguously reveal that prior or current history of non-vegetarian diet, smoking and alcohol can significantly alter the expression of IER-3, TIMP-3, B3GALTL, LIPC and HTRA1, suggesting the involvement of prior exposure of these habits as responsible for changes that may activate the age related molecular and cellular mechanisms. However, not many studies have revealed the association and biological significance of sleeping hours on AMD pathology. Khurana et al (2016) reported the high chance of geographic atrophy with increase in sleeping hours [24]. Similarly, short sleep has also been reported to be associated with increased susceptibility of AMD [25]. Similarly, our results from regression anlaysis indicate the pathological implication of altered sleeping hours of AMD. This illustrates the mechanistic importance of HTRA1, IER-3 and TIMP-3 in regulation of circadian rhythms. A marginal association was also reported for SLC16A8. Multinomial regression analysis showed a significant contribution of sleeping hours in AMD progression along with existing factors like smoking, alcohol, food habit etc. Temporal protein expressions in differential environmental exposure indicate the plausible role of epigenetics in AMD which has been evident by the 48% higher activity of DNA methyltransferases (DNMTs) in addition to enhanced DNMT1 and DNMT3B levels in AMD as compare to controls. Results also showed the higher methylation of LINE1 in AMD patients [37]. Methylation analysis has demonstrated the epigenetic regulation of SKI, GTF2H4, TNXB and IL17RC genes and their mediated functions in AMD pathology [38, 39].

Gender has additionally been found associated with AMD showing higher susceptibility for females ([40]. However, we did not find any significant difference in frequency between AMD females and males. Surprisingly, contrast estimate results showed differential expression of SLC16A8 and LIPC between control male and female (was not seen among AMD male and female) which may support the sex susceptibility and gender polarization hypothesis in the context of ADL. However, hormonal difference between both genders, their different cellular and molecular action, along with association with SLC16A8 and LIPC, has not been investigated in this report.

5. Conclusion

Conclusively, consideration of environmental factor, sleeping patterns and genetics of an individual must be profiled in order to provide the precise diagnostic and therapeutic benefit to AMD patients. Genetic interaction, gene-protein interaction and gene-environmental interaction, along with nature of interactions and investigation of epigenetic pattern, can enable us to understand the penetrance of each component while facilitating personalized medicine hypothesis. Moreover, exploratory studies to examine the multiple genetic variations (especially in heterogenic disease like AMD), the degree of genetic penetrance of ‘hot spots’ or other genetic variants (mutation penetrance) may develop various genetic recombinant phenotypes (with varied genetic interactions) for disease pathology under the influence of environmental factors [41, 42]. Hence, complete mapping of genetic interactions, their genetic penetrance, epigenetics status and grading of epistatic interactions under the influence of confounder will provide precise disease phenotype. This could be dealt by modulating the therapeutics. Instead of cellular therapies, herbal or natural therapies could provide benefit in environmental induced age related changes or diseases by regulating the cellular and molecular pathways [4347]. However, this requires an ADL framework for optimal treatment outcome.

6. Strengths and limitations

Study has first time demonstrated the biological significance sleeping pattern, in addition to already existing confounders (e.g. smoking, food habits, alcohol consumption) in AMD pathology by examining the altered expression of prominent biomarkers. Sleeping pattern could regulate the angiogenesis and survival of photoreceptors in AMD pathology as indicated by results described in Table 4. Moreover, interesting involvement of SLC16A8 and LIPC (Table 5) in protection mechanism has also provided the pilot data for further investigation in field of AMD which suggest further diversification and complexity of AMD to strengthen the diagnostics and therapeutic outcome accordingly [48]. This led hamper the clinical translation in neurodegenerative diseases including Alzheimers disease and AMD [18, 49]. However, further validation and replication of the results must be reconfirmed in larger cohort (by including Asian and Caucasian population) with precise mechanism of AMD pathogenesis.

Supporting information

S1 File. Sleeping pattern and activities of daily living modulate protein expression in AMD (PONE-D-20-29337R1).

(DOCX)

Acknowledgments

We sincerely acknowledge all the participants who were involved in the study. We are also thankful to staff of Neuroscience Research Lab. We also sincerely acknowledge Dr Pramod Avti, Department of Biophysics, Post Graduate Institute of Medical Education and Research, Chandigarh, India for the further editing of the manuscript.

Data Availability

All relevant data are in the paper and its Supporting Information files.

Funding Statement

This study was funded by the Department of Biotechnology, New Delhi, India to AA (No. BT/PR17550/MED/30/1755/2016). We also acknowledge CSIR-UGC, New Delhi for providing fellowship during PhD to KS, Department of Science and Technology (DST), New Delhi, India and Indian Council of Medical Research (ICMR), New Delhi, India to provide the travel funds to KS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Sharma K, Sharma NK, Anand A. Why AMD is a disease of ageing and not of development: mechanisms and insights. Front Aging Neurosci. 2014;6:151. Epub 2014/07/30. 10.3389/fnagi.2014.00151 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Anand A, Sharma K, Sharma SK, Singh R, Sharma NK, Prasad K. AMD Genetics in India: The Missing Links. Front Aging Neurosci. 2016;8:115. Epub 2016/06/03. 10.3389/fnagi.2016.00115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Fritsche LG, Chen W, Schu M, Yaspan BL, Yu Y, Thorleifsson G, et al. Seven new loci associated with age-related macular degeneration. Nat Genet. 2013;45(4):433–9, 9e1-2. Epub 2013/03/05. 10.1038/ng.2578 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Takeuchi A, Takeuchi M, Oikawa K, Sonoda KH, Usui Y, Okunuki Y, et al. Effects of dioxin on vascular endothelial growth factor (VEGF) production in the retina associated with choroidal neovascularization. Invest Ophthalmol Vis Sci. 2009;50(7):3410–6. Epub 2009/02/03. 10.1167/iovs.08-2299 . [DOI] [PubMed] [Google Scholar]
  • 5.Wills NK, Ramanujam VM, Chang J, Kalariya N, Lewis JR, Weng TX, et al. Cadmium accumulation in the human retina: effects of age, gender, and cellular toxicity. Exp Eye Res. 2008;86(1):41–51. Epub 2007/10/31. 10.1016/j.exer.2007.09.005 . [DOI] [PubMed] [Google Scholar]
  • 6.Velilla S, García-Medina JJ, García-Layana A, Dolz-Marco R, Pons-Vázquez S, Pinazo-Durán MD, et al. Smoking and age-related macular degeneration: review and update. J Ophthalmol. 2013;2013:895147. Epub 2013/12/26. 10.1155/2013/895147 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Kunchithapautham K, Atkinson C, Rohrer B. Smoke exposure causes endoplasmic reticulum stress and lipid accumulation in retinal pigment epithelium through oxidative stress and complement activation. J Biol Chem. 2014;289(21):14534–46. Epub 2014/04/09. 10.1074/jbc.M114.564674 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Venza I, Visalli M, Oteri R, Teti D, Venza M. Combined effects of cigarette smoking and alcohol consumption on antioxidant/oxidant balance in age-related macular degeneration. Aging Clin Exp Res. 2012;24(5):530–6. Epub 2012/06/27. 10.3275/8477 . [DOI] [PubMed] [Google Scholar]
  • 9.Anand A, Sharma NK, Gupta A, Prabhakar S, Sharma SK, Singh R. Superoxide dismutase1 levels in North Indian population with age-related macular degeneration. Oxid Med Cell Longev. 2013;2013:365046. Epub 2013/12/24. 10.1155/2013/365046 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Sharma K, Sharma NK, Singh R, Anand A. Exploring the role of VEGF in Indian Age related macular degeneration. Ann Neurosci. 2015;22(4):232–7. Epub 2015/11/04. 10.5214/ans.0972.7531.220408 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Sharma NK, Gupta A, Prabhakar S, Singh R, Sharma S, Anand A. Single nucleotide polymorphism and serum levels of VEGFR2 are associated with age related macular degeneration. Curr Neurovasc Res. 2012;9(4):256–65. Epub 2012/10/04. 10.2174/156720212803530681 . [DOI] [PubMed] [Google Scholar]
  • 12.Sharma NK, Sharma K, Singh R, Sharma SK, Anand A. CCL2 single nucleotide polymorphism of rs1024611 implicates prominence of inflammatory cascade by univariate modeling in Indian AMD. PLoS One. 2018;13(4):e0193423. Epub 2018/04/18. 10.1371/journal.pone.0193423 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Sharma NK, Gupta A, Prabhakar S, Singh R, Bhatt AK, Anand A. CC chemokine receptor-3 as new target for age-related macular degeneration. Gene. 2013;523(1):106–11. Epub 2013/04/10. 10.1016/j.gene.2013.03.052 . [DOI] [PubMed] [Google Scholar]
  • 14.Anand A, Sharma NK, Gupta A, Prabhakar S, Sharma SK, Singh R, et al. Single nucleotide polymorphisms in MCP-1 and its receptor are associated with the risk of age related macular degeneration. PLoS One. 2012;7(11):e49905. Epub 2012/11/28. 10.1371/journal.pone.0049905 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Anand A, Gupta PK, Sharma NK, Prabhakar S. Soluble VEGFR1 (sVEGFR1) as a novel marker of amyotrophic lateral sclerosis (ALS) in the North Indian ALS patients. Eur J Neurol. 2012;19(5):788–92. Epub 2011/10/08. 10.1111/j.1468-1331.2011.03548.x . [DOI] [PubMed] [Google Scholar]
  • 16.Gupta PK, Prabhakar S, Abburi C, Sharma NK, Anand A. Vascular endothelial growth factor-A and chemokine ligand (CCL2) genes are upregulated in peripheral blood mononuclear cells in Indian amyotrophic lateral sclerosis patients. J Neuroinflammation. 2011;8:114. Epub 2011/09/13. 10.1186/1742-2094-8-114 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Anand A, Thakur K, Gupta PK. ALS and oxidative stress: the neurovascular scenario. Oxid Med Cell Longev. 2013;2013:635831. Epub 2013/12/25. 10.1155/2013/635831 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Anand A, Banik A, Thakur K, Masters CL. The animal models of dementia and Alzheimer’s disease for pre-clinical testing and clinical translation. Curr Alzheimer Res. 2012;9(9):1010–29. Epub 2012/06/16. 10.2174/156720512803569055 . [DOI] [PubMed] [Google Scholar]
  • 19.Sharma K, Sharma NK, Singh R, Sharma SK, Anand A. Gene networks determine predisposition to AMD. Genomics. 2020. Epub 2020/09/27. 10.1016/j.ygeno.2020.09.044 . [DOI] [PubMed] [Google Scholar]
  • 20.Gemenetzi M, Lotery AJ. Epigenetics in age-related macular degeneration: new discoveries and future perspectives. Cell Mol Life Sci. 2020;77(5):807–18. Epub 2020/01/04. 10.1007/s00018-019-03421-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Liu MM, Chan CC, Tuo J. Genetic mechanisms and age-related macular degeneration: common variants, rare variants, copy number variations, epigenetics, and mitochondrial genetics. Hum Genomics. 2012;6(1):13. Epub 2012/12/19. 10.1186/1479-7364-6-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Gemenetzi M, Lotery AJ. The role of epigenetics in age-related macular degeneration. Eye (Lond). 2014;28(12):1407–17. Epub 2014/09/23. 10.1038/eye.2014.225 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Baird PN, Wei L. Age-related macular degeneration and DNA methylation. Epigenomics. 2013;5(3):239–41. Epub 2013/06/12. 10.2217/epi.13.19 . [DOI] [PubMed] [Google Scholar]
  • 24.Khurana RN, Porco TC, Claman DM, Boldrey EE, Palmer JD, Wieland MR. INCREASING SLEEP DURATION IS ASSOCIATED WITH GEOGRAPHIC ATROPHY AND AGE-RELATED MACULAR DEGENERATION. Retina. 2016;36(2):255–8. Epub 2016/01/28. 10.1097/IAE.0000000000000706 . [DOI] [PubMed] [Google Scholar]
  • 25.Pérez-Canales JL, Rico-Sergado L, Pérez-Santonja JJ. Self-Reported Sleep Duration in Patients with Neovascular Age-Related Macular Degeneration. Ophthalmic Epidemiol. 2016;23(1):20–6. Epub 2016/01/21. 10.3109/09286586.2015.1119288 . [DOI] [PubMed] [Google Scholar]
  • 26.Luu J, Palczewski K. Human aging and disease: Lessons from age-related macular degeneration. Proc Natl Acad Sci U S A. 2018;115(12):2866–72. Epub 2018/02/28. 10.1073/pnas.1721033115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Cascella R, Strafella C, Caputo V, Errichiello V, Zampatti S, Milano F, et al. Towards the application of precision medicine in Age-Related Macular Degeneration. Prog Retin Eye Res. 2018;63:132–46. Epub 2017/12/05. 10.1016/j.preteyeres.2017.11.004 . [DOI] [PubMed] [Google Scholar]
  • 28.Cascella R, Strafella C, Longo G, Ragazzo M, Manzo L, De Felici C, et al. Uncovering genetic and non-genetic biomarkers specific for exudative age-related macular degeneration: significant association of twelve variants. Oncotarget. 2018;9(8):7812–21. Epub 2018/03/01. 10.18632/oncotarget.23241 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Winkler TW, Brandl C, Grassmann F, Gorski M, Stark K, Loss J, et al. Investigating the modulation of genetic effects on late AMD by age and sex: Lessons learned and two additional loci. PLoS One. 2018;13(3):e0194321. Epub 2018/03/13. 10.1371/journal.pone.0194321 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Maugeri A, Barchitta M, Mazzone MG, Giuliano F, Agodi A. Complement System and Age-Related Macular Degeneration: Implications of Gene-Environment Interaction for Preventive and Personalized Medicine. Biomed Res Int. 2018;2018:7532507. Epub 2018/09/19. 10.1155/2018/7532507 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Chen Y, Zeng J, Zhao C, Wang K, Trood E, Buehler J, et al. Assessing susceptibility to age-related macular degeneration with genetic markers and environmental factors. Arch Ophthalmol. 2011;129(3):344–51. Epub 2011/03/16. 10.1001/archophthalmol.2011.10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Sharma NK, Gupta A, Prabhakar S, Singh R, Sharma SK, Chen W, et al. Association between CFH Y402H polymorphism and age related macular degeneration in North Indian cohort. PLoS One. 2013;8(7):e70193. Epub 2013/08/08. 10.1371/journal.pone.0070193 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Sharma NK, Sharma K, Gupta A, Prabhakar S, Singh R, Gupta PK, et al. Does toll-like receptor-3 (TLR-3) have any role in Indian AMD phenotype? Mol Cell Biochem. 2014;393(1–2):1–8. Epub 2014/04/01. 10.1007/s11010-014-2040-4 . [DOI] [PubMed] [Google Scholar]
  • 34.Sharma K, Tyagi R, Singh R, Sharma SK, Anand A. Serum Levels of TIMP-3, LIPC, IER3, and SLC16A8 in CFH-Negative AMD Cases. J Cell Biochem. 2017;118(8):2087–95. Epub 2016/12/15. 10.1002/jcb.25837 . [DOI] [PubMed] [Google Scholar]
  • 35.Sharma NK, Prabhakar S, Gupta A, Singh R, Gupta PK, Gupta PK, et al. New biomarker for neovascular age-related macular degeneration: eotaxin-2. DNA Cell Biol. 2012;31(11):1618–27. Epub 2012/10/03. 10.1089/dna.2012.1786 . [DOI] [PubMed] [Google Scholar]
  • 36.Sharma NK, Sharma SK, Gupta A, Prabhakar S, Singh R, Anand A. Predictive model for earlier diagnosis of suspected age-related macular degeneration patients. DNA Cell Biol. 2013;32(9):549–55. Epub 2013/07/16. 10.1089/dna.2013.2072 . [DOI] [PubMed] [Google Scholar]
  • 37.Maugeri A, Barchitta M, Fallico M, Castellino N, Reibaldi M, Agodi A. Characterization of SIRT1/DNMTs Functions and LINE-1 Methylation in Patients with Age-Related Macular Degeneration. J Clin Med. 2019;8(2). Epub 2019/02/06. 10.3390/jcm8020159 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Porter LF, Saptarshi N, Fang Y, Rathi S, den Hollander AI, de Jong EK, et al. Whole-genome methylation profiling of the retinal pigment epithelium of individuals with age-related macular degeneration reveals differential methylation of the SKI, GTF2H4, and TNXB genes. Clin Epigenetics. 2019;11(1):6. Epub 2019/01/16. 10.1186/s13148-019-0608-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Wei L, Liu B, Tuo J, Shen D, Chen P, Li Z, et al. Hypomethylation of the IL17RC promoter associates with age-related macular degeneration. Cell Rep. 2012;2(5):1151–8. Epub 2012/11/28. 10.1016/j.celrep.2012.10.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Fernandez-Robredo P, Recalde S, Hernandez M, Zarranz-Ventura J, Molins B, Casaroli-Marano RP, et al. Novel Association of High C-Reactive Protein Levels and A69S at Risk Alleles in Wet Age-Related Macular Degeneration Women. Front Immunol. 2018;9:1862. Epub 2018/08/30. 10.3389/fimmu.2018.01862 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Zhou J, McCandlish DM. Minimum epistasis interpolation for sequence-function relationships. Nat Commun. 2020;11(1):1782. Epub 2020/04/15. 10.1038/s41467-020-15512-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Wang Y, Liu X, Robbins K, Rekaya R. AntEpiSeeker: detecting epistatic interactions for case-control studies using a two-stage ant colony optimization algorithm. BMC Res Notes. 2010;3:117. Epub 2010/04/30. 10.1186/1756-0500-3-117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Anand A, Saraf MK, Prabhakar S. Sustained inhibition of brotizolam induced anterograde amnesia by norharmane and retrograde amnesia by L-glutamic acid in mice. Behav Brain Res. 2007;182(1):12–20. Epub 2007/06/15. 10.1016/j.bbr.2007.04.022 . [DOI] [PubMed] [Google Scholar]
  • 44.Anand A, Saraf MK, Prabhakar S. Antiamnesic effect of B. monniera on L-NNA induced amnesia involves calmodulin. Neurochem Res. 2010;35(8):1172–81. Epub 2010/05/01. 10.1007/s11064-010-0171-x . [DOI] [PubMed] [Google Scholar]
  • 45.Mathur D, Goyal K, Koul V, Anand A. The Molecular Links of Re-Emerging Therapy: A Review of Evidence of Brahmi (Bacopa monniera). Front Pharmacol. 2016;7:44. Epub 2016/03/15. 10.3389/fphar.2016.00044 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Singh T, Prabhakar S, Gupta A, Anand A. Recruitment of stem cells into the injured retina after laser injury. Stem Cells Dev. 2012;21(3):448–54. Epub 2011/05/13. 10.1089/scd.2011.0002 . [DOI] [PubMed] [Google Scholar]
  • 47.English D, Sharma NK, Sharma K, Anand A. Neural stem cells-trends and advances. J Cell Biochem. 2013;114(4):764–72. Epub 2012/12/12. 10.1002/jcb.24436 . [DOI] [PubMed] [Google Scholar]
  • 48.Anand A, Sharma K, Chen W, Sharma NK. Using current data to define new approach in age related macular degeneration: need to accelerate translational research. Curr Genomics. 2014;15(4):266–77. Epub 2014/08/19. 10.2174/1389202915666140516204512 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Banik A, Brown RE, Bamburg J, Lahiri DK, Khurana D, Friedland RP, et al. Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer’s Disease: What are the Roadblocks and How Can They Be Overcome? J Alzheimers Dis. 2015;47(4):815–43. Epub 2015/09/25. 10.3233/JAD-150136 . [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Alfred S Lewin

6 Nov 2020

PONE-D-20-29337

Sleeping pattern and activities of daily living modulate protein expression in AMD

PLOS ONE

Dear Dr. Anand,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please evaluate the role of epigenetic changes in the onset and progression of AMD.

Please submit your revised manuscript by Dec 21 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Alfred S Lewin, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your Methods section, please provide additional information about the participant recruitment method and the demographic details of your participants. Please ensure you have provided sufficient details to replicate the analyses such as: a) the recruitment date range (month and year), b) a description of any inclusion/exclusion criteria that were applied to participant recruitment, c) a table of relevant demographic details, d) a statement as to whether your sample can be considered representative of a larger population, e) a description of how participants were recruited, and f) descriptions of where participants were recruited and where the research took place.

3.We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.  

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services.  If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.

Upon resubmission, please provide the following:

  • The name of the colleague or the details of the professional service that edited your manuscript

  • A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file)

  • A clean copy of the edited manuscript (uploaded as the new *manuscript* file)

4.We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

5.Thank you for stating the following in the Acknowledgments Section of your manuscript:

[Department of Biotechnology (No. BT/PR17550/MED/30/1755/2016), New Delhi,

India. The funders had no role in study design, data collection and analysis, decision to publish,

or preparation of the manuscript.]

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

 [The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.]

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The manuscript is interesting and well organized. The methods selected and applied for the analyzes are correct and adequate. As the rationale of the paper evaluates "Sleeping pattern and activities of daily living" it is also crucial to discuss the possible role of epigenetics in the onset and progression of AMD. Numerous papers have been published in the literature describing a possible role of epigenetic mechanisms in the etiopathogenesis of the disease. This topic should be included in both the introduction and discussion with the aim of improving the originality of the manuscript.

To date, when studying multifactorial diseases it is very important to take into account the role of epigenetics.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Jun 1;16(6):e0248523. doi: 10.1371/journal.pone.0248523.r002

Author response to Decision Letter 0


26 Jan 2021

PONE-D-20-29337

Sleeping pattern and activities of daily living modulate protein expression in AMD

Dear Editor

We have addressed all the comments raised by the reviewers and modified the manuscript as per journal requirements. Please see revised manuscript for your kind consideration.

Please evaluate the role of epigenetic changes in the onset and progression of AMD.

Response: We have added the requisite literature to support our results of the manuscript. Thanks for valuable comment.

Sincerely

Akshay Anand, PhD

Professor

Neuroscience Research lab

Department of Neurology

PGIMER, Chandigarh, India.

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response: Thanks for comment. Manuscript has been changed as per the template provided.

2. In your Methods section, please provide additional information about the participant recruitment method and the demographic details of your participants. Please ensure you have provided sufficient details to replicate the analyses such as: a) the recruitment date range (month and year), b) a description of any inclusion/exclusion criteria that were applied to participant recruitment, c) a table of relevant demographic details, d) a statement as to whether your sample can be considered representative of a larger population, e) a description of how participants were recruited, and f) descriptions of where participants were recruited and where the research took place.

Response 2: a) the recruitment date range (month and year)

Response: The methodology has been updated as per the reviewer comment.

b). a description of any inclusion/exclusion criteria that were applied to participant recruitment.

Response: We have expanded the inclusion criteria of the manuscript, based on which we have recruited the participants.

c) a table of relevant demographic details

Response: Thanks for the comment. We have mentioned the socio-demographic characteristics of the recruited participants in Table 1, 2 and 3. Please see for your kind consideration.

d) a statement as to whether your sample can be considered representative of a larger population.

Response: We have added the statement as reviewer suggested. Please see ‘Recruitment of participants’ section of the manuscript.

e) a description of how participants were recruited.

Response: The recruitment of the participants was done as per the inclusion and exclusion criteria of the study as mentioned in the ‘inclusion criteria and recruitment of participants’ sections of the manuscript.

f) descriptions of where participants were recruited and where the research took place.

Response: The recruitment of participants and clinical examination were done from Department of Ophthalmology, PGIMER, Chandigarh, India and experiments were conducted in Neuroscience Research Lab, Dept of Neurology, Post Graduate Institute of medical Education and Research, Chandigarh, India. We have updated the recruitment of participants section as per the reviewer comment.

3. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.

Response: We have substantially edited the manuscript with native English to enhance the readability of the same. We have also acknowledges the same in the ‘acknowledgment section’ of the manuscript. Thanks for your comment.

Upon resubmission, please provide the following:

• The name of the colleague or the details of the professional service that edited your manuscript

• A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file)

• A clean copy of the edited manuscript (uploaded as the new *manuscript* file)

Response: Dr Pramod Avti, associate Professor, Department of Biophysics, Post Graduate Institute of Medical Education and Research has help us in editing of the manuscript. We are thankful and acknowledged the same in the manuscript.

4. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

Response: We have already published an article on genetic analysis which is accessible in the pubmed portal without any restriction (doi:10.1016/j.ygeno.2020.09.044).

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

Response: Not applicable.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Response: We have recently published an article and could be used as data source for current manuscript (doi: 10.1016/j.ygeno.2020.09.044). Meanwhile, we will initiate the process to upload the data in public repository.

5. Thank you for stating the following in the Acknowledgments Section of your manuscript:

[Department of Biotechnology (No. BT/PR17550/MED/30/1755/2016), New Delhi,

India. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.]

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

[The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.]

Response: We have removed the funding statement from the manuscript as per the suggestion of the reviewer.

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Response: Please write the funding statement as “Department of Biotechnology (No. BT/PR17550/MED/30/1755/2016), New Delhi, India and no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript”.

Reviewers' comments:

Reviewer's Responses to Questions

Reviewer #1: The manuscript is interesting and well organized. The methods selected and applied for the analyzes are correct and adequate. As the rationale of the paper evaluates "Sleeping pattern and activities of daily living" it is also crucial to discuss the possible role of epigenetics in the onset and progression of AMD. Numerous papers have been published in the literature describing a possible role of epigenetic mechanisms in the etiopathogenesis of the disease. This topic should be included in both the introduction and discussion with the aim of improving the originality of the manuscript.

To date, when studying multifactorial diseases it is very important to take into account the role of epigenetics.

Response: Thanks for valuable comment. We have updated the manuscript by discussing the significance of epigenetic modification and its implication in genetic and pathological complexity of AMD. Please see introduction and discussion sections of the manuscript.

Attachment

Submitted filename: Rebuttal letter.docx

Decision Letter 1

Alfred S Lewin

1 Mar 2021

Sleeping pattern and activities of daily living modulate protein expression in AMD

PONE-D-20-29337R1

Dear Dr. Anand,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Alfred S Lewin, Ph.D.

Section Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Acceptance letter

Alfred S Lewin

21 May 2021

PONE-D-20-29337R1

Sleeping pattern and activities of daily living modulate protein expression in AMD

Dear Dr. Anand:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Alfred S Lewin

Section Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Sleeping pattern and activities of daily living modulate protein expression in AMD (PONE-D-20-29337R1).

    (DOCX)

    Attachment

    Submitted filename: Rebuttal letter.docx

    Data Availability Statement

    All relevant data are in the paper and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES